Global CDMO Companies Gather in One Place at BIX 2023

Lonja, Ushibio, and Fujifilm Participate
Domestic Companies like SK Bioscience, Daewoong Pharmaceutical, and GC Cell Also
"Major Deployment of Global CDMO Companies"

Global top-tier contract development and manufacturing organizations (CDMOs) will set up booths and promote themselves at 'BioPlus-InterPhex Korea 2023' (hereinafter BIX), a bio convention opening this month.

BIX 2023 Poster. [Image provided by Korea Bio Association]

The Korea Bio Association announced on the 3rd that BIX 2023, a comprehensive bio convention co-hosted with RX Korea, will be held from the 12th to the 14th at COEX in Gangnam-gu, Seoul. In the exhibition sector of this event, global CDMO companies such as Lonza, WuXi Biologics, and Fujifilm will participate.

Lonza, headquartered in Switzerland, currently ranks first worldwide in CDMO sales and possesses large-scale biopharmaceutical manufacturing capabilities. Lonza, a major production partner of Moderna's COVID-19 vaccine, signed a collaboration agreement in April with the Korean company ABL Bio for the development and production of bispecific antibody drug candidates. At this event, Lonza will not only have a booth but also conduct a standalone corporate session in the seminar hall and hold a pre-invitation reception to attract domestic customers.

China's WuXi Biologics is building a contract research, development, and manufacturing organization (CRDMO) model emphasizing strengthening its research division, leading to growth in sales scale and profitability. Additionally, according to the association, WuXi is advancing in issues such as improving the global supply chain, using clean energy, non-clinical services related to animal testing, and ESG (environmental, social, and governance) matters.

Japan's Fujifilm provides CDMO services based on lipid nanoparticles (LNP) and liposomes. On the 6th of last month, it established 'Fujifilm Diosynth Biotechnologies Japan (FDBJ),' an Asia-dedicated bio CDMO service corporation in Tokyo, and began operations on the 3rd, officially joining the global CDMO market competition.

In addition, BIX 2023 will gather domestic and international companies in the contract manufacturing (CMO) and CDMO sectors, including global companies such as Vetter, Catalent, and AGC, as well as Korean companies like SK Bioscience, STGen Bio, Kolon, Daewoong Pharmaceutical, Medipost, Prestige Biologics, and GC Cell.

Lee Seung-gyu, Vice Chairman of the Korea Bio Association, said, "It is very unusual that global CDMO companies from Korea, China, Japan, and beyond have gathered in large numbers in our country," adding, "Through this BIX, we aim to actively promote the strengths of domestic and international CDMO companies."

Meanwhile, according to a report by global market research firm Frost & Sullivan, the global bio CDMO market is expected to reach $47.7 billion (approximately 61.056 trillion KRW) by 2028.

This content was produced with the assistance of AI translation services.